4 February 2014 Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy
Author Affiliations +
J. of Biomedical Optics, 19(2), 025001 (2014). doi:10.1117/1.JBO.19.2.025001
Abstract
The overexpression of human epidermal growth factor receptor 2 (HER2) is associated with increased breast cancer recurrence and worse prognosis. Effective treatments such as trastuzumab and lapatinib for patients with HER2 overexpression target the blockade of HER2 signaling activities but are often limited by the emergence of acquired drug resistance. This study applied Raman spectroscopy to differentially identify the amplification status of HER2 in cells and to characterize the biochemical composition of lapatinib resistant and sensitive HER2+ breast cancer cells in response to the drug. Raman spectra from BT474 (HER2+ breast cancer cell), MCF-10A (HER2− control), and HER2+ MCF-10A (HER2+ control) were analyzed using lasso and elastic-net regularized generalized linear models (glmnet) for multivariate statistical analysis and were discriminated to groups of different HER2 expression status with an overall 99% sensitivity and specificity. Enhanced lipid content and decreased proteome were observed in HER2+ cells. With lapatinib treatment, lapatinib-resistant breast cancer cells demonstrated sustained lipogenesis compared with the sensitive cells.
Bi, Rexer, Arteaga, Guo, and Mahadevan-Jansen: Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy

1.

Introduction

The human epidermal growth factor receptor 2 (HER2) protein and the HER2/neu oncogene make an important contribution to the regulation of cell proliferation and survival. Amplification of HER2/neu gene occurs in approximately 20% to 25% of human breast cancers12.3 and is associated with a more aggressive disease course and poor prognosis.3,4 Besides increased disease recurrence and short survival, HER2 amplification status is predictive for resistance to certain endocrine and chemotherapeutic agents.5,6 Patients with HER2+ breast cancer require specific treatments targeting blockade of HER2 activity with monoclonal antibodies [e.g., trastuzumab (Herceptin)] and small molecule tyrosine kinase inhibitors (e.g., lapatinib). Therefore, assessment of HER2 status is pivotal in therapeutic decision making for breast cancer patients.

Current testing for amplification of HER2/neu gene relies on two validated techniques: immunohistochemical (IHC) analysis and fluorescence in situ hybridization (FISH). The IHC analysis stains HER2 protein on the cytoplasmic membrane through specific antibody and scores protein expression status based on the color of the stains. This qualitative test is subjected to interlaboratory variation and is relatively less sensitive than FISH. The FISH targets the encoding DNA and thus directly probes HER2 gene amplification. The main disadvantages of this method include the expensive cost and time-consuming analysis that can take days. Although both assays are extensively used in routine clinical diagnosis, the discrepancy between IHC and FISH varies from 3% to 50% (Refs. 78.9.10.11). A combined FISH and IHC approach was suggested to achieve more efficient outcome. Development of new methodologies that can provide accurate and objective determinations on HER2 status is desirable.

Despite significant response rate, a significant proportion of HER2+ breast cancer patients still relapse and develop therapeutic resistance to HER2-targeted regimens such as lapatinib and trastuzumab. Lapatinib is a dual small molecule tyrosine kinase inhibitor that inhibits both epidermal growth factor receptor and HER2. Treatment with lapatinib has been shown to inhibit downstream signaling pathways of HER2 including PI3K-Akt.12 It has shown antitumor activity both in vitro and in vivo by inhibiting cell proliferation and inducing apoptosis.13,14 Because lapatinib was approved only recently, patient cohorts in which to interrogate mechanisms of acquired resistance have yet to be established.

Raman spectroscopy (RS) is an optical technique that can detect molecular components or biophysical microenvironment in the tissue. Distinctive Raman signatures have been identified to be arising from biomolecules such as nucleic acids, proteins, and lipids. Diagnostic information can thus be achieved by detecting subtle biochemical changes in multiple biomolecules in diseased tissue. In breast cancer research, RS has been applied to distinguish between malignant, normal, and benign breast tissues with significant sensitivity and specificity.1516.17.18.19 Several groups reported HER2 amplification assessment using surface-enhanced RS (SERS).20,21 However, SERS requires involvement of nanoparticles and antibodies and as such, does not take full advantage of the intrinsic nature of RS. Meanwhile, conventional RS has been successful in collecting Raman spectra from cells and revealed distinct spectral features from the cytoplasm and chromosome of a live single cell.22 Hartsuiker et al. reported significant variance in lipid content among breast carcinoma cell lines with varying expression levels of HER2.23 However, the aforementioned study only provided qualitative analysis on the biochemical properties of single cells and did not explore the potential of RS in differentiating cells based on HER2 status. The goal of the present article is to utilize RS along with multivariate statistical analysis to evaluate the feasibility of this technique in determining HER2 amplification status. Given the sensitivity of RS in detecting molecular phenotypes of cells, it is further applied to characterize the acquired drug resistance of HER2+ breast cancer cells to lapatinib. Instead of interrogating single cells at subcellular level, the ultimate goal of the current study is to characterize HER2-associated biochemical variances at the tissue level, and thus a collection of cells in pellets was investigated in this article. The HER2 overexpressing breast cancer cell line BT474 and breast epithelial cell line MCF-10A with and without HER2 amplification (as positive and negative controls) were compared. Breast cancer cells with acquired lapatinib resistance were also characterized by RS and compared with lapatinib-sensitive breast cancer cells BT474.

2.

Materials and Methods

2.1.

Cell Lines

Totally four different cell lines were investigated in this study (Table 1) including human breast cancer cell line BT474 that overexpresses HER2 protein, human breast epithelial cell MCF-10A with HER2 amplification (HER2+ control), MCF-10A without HER2 amplification (HER2− control), and BT474 with acquired lapatinib resistance. The controls were obtained by transducing MCF-10A cells with a retroviral vector-encoding human HER2 or with vector alone, as previously described.24 To generate drug-resistant cells, HER2+ breast cancer cells BT474 were cultured in increasing concentrations of lapatinib, following published methods.2526.27 BT474 cells exhibit an IC50 to lapatinib of 0.1μM (Ref. 14). At this time, BT474 lapatinib-resistant cells are growing in the laboratory in the presence of 2-μM lapatinib, whereas the parental BT474 serves as drug-sensitive cells. Both lapatinib resistant and sensitive cells were treated with lapatinib overnight (12 to 16 h) before being processed for RS measurements.

Table 1

Cell lines investigated in the current study. Raman spectra were collected from multiple batches of cell culture from each group of cells. The lapatinib sensitive and resistant breast cancer cells were treated with lapatinib before spectral acquisition.

GroupCell line SourceBatch of cell cultureTotal spectra
HER2+ human breast cancer cellsBT4745132
HER2+ controlMCF-10A with HER2479
HER2− controloverexpression MCF-10A with vector361
Lapatinib sensitive-breast cancer cellsBT4744>100
Lapatinib resistant-breast cancer cellsBT474 with acquired resistance4104

All the cell lines were seeded in Petri dishes at a density of 1×106cellml1 and grown in a Dulbecco’s modified Eagle medium in a humidified 5% CO2 atmosphere at 37°C. The cells were scrapped free from the dish using a disposable cell scraper, transferred to a 15-ml centrifuge tube, and centrifuged at 1000 rpm for 3 min at room temperature. The supernatant was aspirated, and the cells were washed by three series of saline, followed by centrifugation at 1000 rpm for 3 min after each wash. After the last wash, the cell pellets were transferred to a quartz microscope slide for Raman measurement.

2.2.

Raman Spectra Collection

Raman spectra were acquired using a confocal Raman microspectroscopy (Ramascope Mark III, Renishaw Inc., Gloucestershire, United Kingdom) with a 785-nm diode laser (Innovative Photonic Solutions, Monmouth Junction, New Jersey). Each spectrum was acquired through a 50×/0.75NA objective (Leica Microsystems Inc., Buffalo Grove, Illinois, 50× N Plan) using 30-s exposure time and two accumulations with a laser power of 30 mW on the sample. Raman shift of the collected spectra is 300 to 1800cm1, and the spectral resolution is 3cm1. Multiple spectra were acquired from each pellet. A summary of cell lines and the total number of spectra from each group is listed in Table 1. Background spectrum of the quartz slide was subtracted from each sample spectrum using the “automatic spectral subtraction function” in GRAMS/AI spectroscopy software (Thermo Fisher Scientific Inc., Waltham, Massachusetts). The resulting spectrum equals to the source sample spectrum minus a factored background. The final background factor is automatically determined by iteratively subtracting the background multiplied by various factors in the range of 0 to 2 in a step of 0.0001 until the residual reaches the tolerance of 1e-6. Fluorescence background was subtracted using an automated modified polynomial fitting method written in MATLAB (MathWorks, Natick, Massachusetts).28 To account for inherent variation in intra- and intersample absolute signal intensities, the spectra were normalized to their respective mean intensity in the fingerprint range of Raman shift 700 to 1750cm1 (Ref. 29).

2.3.

Data Analysis and Discrimination Algorithm Development

Raman spectra were pooled and analyzed using high-dimension multivariate statistical method in R package called glmnet. A fast and probability-based algorithm for high-dimension discrimination with lasso and elastic-net regularized generalized linear models (glmnet) was applied to classify the cell lines using k-fold cross-validation by k=5. Glmnet method includes both ridge-regression and lasso penalties for optimally reducing the dimensions through elastic-net. The glmnet package in R allows the data to be fit to follow the probability distributions with multivariate statistical models such as linear, logistic and multinomial, Poisson, and Cox regression models. Here, we used logistic and multinomial model for the analysis purpose by the parameter family “multinomial.” The misclassification rate was set up as the optimal destination to find out the minimum misclassification rate for the best discrimination status under a specific selection of the parameter lambda value. The advantages of glmnet method are its flexibility to include a wide range of common situations and to work on large high-dimension dataset.30,31

3.

Results and Discussion

3.1.

Comparing HER2+ BT474 Breast Cancer Cells with HER2 Positive and Negative Controls

Raman spectra were collected from HER2+ breast cancer cells BT474, HER2+ control (MCF-10A/HER2), and HER2− control (MCF-10A). The mean spectra with 1× standard deviation (shaded area) are shown in Fig. 1 with offset for clarity in display. Spectral characteristics at various wavenumbers were observed to be different between the cell lines. The spectral regions that showed statistically significant differences across groups are marked with peak positions, which mainly appear in the region of lipid (1304, 1338, and 1660cm1), protein (852, 872, 1003, and 1260cm1), and nucleic acids (721, 758, 781, and 1088cm1) bands.3233.34 The Raman bands centered in the region of 1440 to 1450cm1 and at 1304cm1 arise from CH2 deformation modes of protein and lipids35,36 and thus will be assigned in this study along with other accompanying bands for both molecules.

Fig. 1

Mean spectra from HER2+ breast cancer cells. HER2− control (a), HER2+ control (b), and BT474 (c) with 1× standard deviation (shaded area). For clarity in display, spectra were offset from the baseline. The scale bar indicates the intensity of Raman scattering unit. Selected spectral bands with statistically significant differences (p<0.05) among the cell lines are labeled with peak positions.

JBO_19_2_025001_f001.png

To further investigate the biochemical differences between the cell lines, spectra were subtracted to reveal the difference between HER2+ BT474 cancer cells and controls. The difference spectra were calculated by subtracting the normalized mean spectrum from HER2+ control from HER2− control [Fig. 2(a)] as well as BT474 from HER2− [Fig. 2(b)] and HER2+ [Fig. 2(c)] controls. Increased nucleic acid content in cancer cells is revealed by the positive difference at 752 and 1088cm1 that were assigned to the phosphodiester groups in nucleic acids (p<0.05, Figs. 2(b) and 2(c)].34 Slightly enhanced nucleic acid content was also observed in the difference spectra between HER2+ and HER2− controls [p<0.01, Fig. 2(a)], indicating that HER2 overexpression leads to active cell proliferation. The intense positive difference at 1594cm1 [Figs. 2(b) and 2(c)] can be attributed to the ring CC stretch vibrations of nucleic acids,37,38 in agreement with the elevation of nucleic acid content in HER2+ cells indicated by 752 and 1088cm1.

Fig. 2

Difference spectra of HER2+ control/HER2− control (a), HER2+ BT474 cancer cells/HER2− control (b), and HER2+ BT474 cancer cells/HER2+ control (c) with offset for display. The straight lines mark the original y=0 line for each difference spectrum. Selective spectral bands with significant differences (p<0.05) among the cell lines are marked with peak positions.

JBO_19_2_025001_f002.png

The difference spectra of BT474 to the controls [Figs. 2(b) and 2(c)] suggest decreased proteome with HER2 amplification by the strong negative spectral features at the amide III (1247 and 1270/1278) and 1438cm1 (p<0.01). The latter has previously been assigned to CH2 and CH3 deformations in the side chain of collagen in normal breast tissue.33,39,40 The protein amide I band at 1650cm1 did not show consistent variation as amide III or the band at 1438cm1, which confounded the interpretation on proteome content in the current study. The Raman bands at 1003 and 1625cm1 arise from the ring structures of phenylalanine and tryptophan/tyrosine, respectively.41,42 Both bands are more intense in cancer cells [Fig. 2(b) and 2(c), p<0.01), suggesting possible elevation in the expression of such aromatic amino acids rich proteins.

The positive difference at 1344cm1 in Figs. 2(b) and 2(c) arises from the wagging mode of CH2 and CH3 in lipids or proteins.40 This enhancement along with the concurrent increase (p<0.01) at 1666cm1, which was assigned to the CC stretching in unsaturated lipids,40 indicates elevated lipid content in HER2+ BT474 cancer cells. HER2+ control also demonstrates a slight increase in lipid composition than HER2− control evidenced by the positive difference at 1457 and 1663cm1 [Fig. 2(a), p<0.05].

The enhanced lipid content in breast cancer cells comes from exacerbated synthesis of fatty acid and phospholipids.43 The lipogenesis regulated by fatty acid synthase is associated with upregulation of HER1/HER2 tyrosine kinase receptors in the cells.44,45 Our study indicates augmented lipogenic process with HER2 overexpression in both cancer and control epithelial cells, suggesting that the excessive HER2 expression might play an important role in promoting the upregulation of fatty acid synthase. This is in agreement with a previous report that the HER2 overexpression stimulates the fatty acid synthase promoter.46

The probability-based multivariate statistical analysis in glmnet was used to discriminate the cell lines and to identify specific spectral features that are important for classification. The confusion matrix for classification from the glmnet analysis is shown in Table 2. The rows of the table show the numbers of spectra measured for each cell line (true), whereas the columns list the number of spectra predicted to each group. The sensitivity and specificity of discrimination for each cell line are calculated by the ratio of true prediction (bold) to the sum of all true values in each row and to the sum of all predicted values in each column, respectively. The spectra from BT474 (131 out of 132) were discriminated from controls with 99.3% sensitivity and 100% specificity. HER2+ and HER2− controls were classified into the correct groups with 100% sensitivity and 98.8% and 100% specificities, respectively, indicating the potential of RS in identifying HER2+ breast cancer cells.

Table 2

The confusion matrix for the classification from glmnet analysis.

Prediction
Cancer cells (BT474)HER2+ controlHER2− control
TrueCancer cells (BT474)13110
HER2+ control0790
HER2− control0061

3.2.

Characterizing Lapatinib-Sensitive HER2+ BT474 Cancer Cells and Lapatinib-Resistant HER2+ BT474 Cancer Cells with Treatment

Mean Raman spectra from lapatinib-treated breast cancer cells (N=104) and lapatinib-resistant cells (N=104) consist of similar band contours with low variations within each group (Fig. 3). Statistical analysis of the spectra showed significant difference (p<0.05) in Raman bands, which are labeled with peak positions on Fig. 3. Phospholipid (1307, 1333, and 1657cm1), protein (855, 1156, and 1173cm1), and nucleic acids (721 and 781cm1) contribute to the major differences between the cell lines.

Fig. 3

Stacked mean Raman spectra from lapatinib-resistant (a) and lapatinib-sensitive (b) breast cancer cells with 1× standard deviation (shaded area). Selective spectral bands with significant differences (p<0.05) among the cell lines are marked with peak positions.

JBO_19_2_025001_f003.png

Figure 4 shows the difference of spectra from lapatinib-resistant and lapatinib-sensitive cells. With lapatinib treatment, drug-resistant cancer cells have a higher phospholipid content with respect to the drug-sensitive cancer cells, as suggested by the positive differences at 778, 1364 and 1384cm1 (Fig. 4, p<0.01). Content of unstatuarated lipids appears decreased as indicated by the negative difference at 1651cm1 (p<0.01). The prominent negative differences at 1282, 1310, 1341, and 1680cm1 reflect decreased proteome in lapatinib-treated drug resistant cells (p<0.05). Significant positive differences are observed at 730 and 778cm1 that arise from the ring breathing of nucleotides,40 indicating enhanced nucleic acid abundance in the drug-resistant cancer cells.

Fig. 4

Difference spectrum of lapatinib-resistant cells with respect to the lapatinib-sensitive cells with treatment. The straight line marks y=0 for reference. Selective spectral bands with significant differences (p<0.05) among the cell lines are marked with peak positions.

JBO_19_2_025001_f004.png

Treatment with lapatinib in drug-sensitive cells blocks HER2 phosphorylation and downstream PI3K-Akt signaling.14,47 Conversely, in resistant cells, lapatinib inhibits HER2 phosphorylation but the PI3K-Akt activity is recovered,27 which involves in the lipogenic pathway in breast cancer cells.48 The greater lipid content indicates active endogenous lipogenesis in drug-resistant cancer cells despite the treatment.

4.

Conclusions

This study reports a sensitive identification of HER2 amplified cell lines, which proves the potential of RS in determining HER2 status in breast cancer cells. Spectral differences reveal variability in HER2-associated biochemical composition in the cell lines. Variation in lipid content is closely related to HER2 status in this study, consistent with previously reported positive regulation between fatty acid synthase and HER2 signaling activities by Menendez et al.45,48 Interestingly, a recent report suggests that targeting fatty acid synthase may be a strategy to overcome resistance to HER2-targeted therapies.49

The biochemical differences detected in the current study are the basis of spectral assessment for HER2 amplification status. Along with multivariate analysis, breast cancer cells can potentially be distinguished in situ by directly importing a blinded test spectrum into the established dataset. Future studies using fiber optics-coupled RS on excised tumor samples can bring this method closer to clinical application in HER2 testing.

To the best of our knowledge, this article represents the first application of RS in characterizing biochemical response of drug resistant and sensitive breast cancer cells to lapatinib treatments. Our findings indicate that RS has the potential to provide a new avenue for studying molecular mechanism of acquired drug resistance as well as evaluating the response of cancer cells to therapeutic treatments.

Acknowledgments

This work was performed in the Biomedical Photonics Laboratory at Vanderbilt University. The authors would like to acknowledge the grant support from National Cancer Institute 2P50 CA098131-06 (C.A.), T32 CA119910 (B.R.), and K25CA149194-01 (X.B.).

References

1. 

M. A. OwensB. C. HortenM. M. Da Silva, “HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues,” Clin. Breast Cancer 5(1), 63–69 (2004).CBCLB71526-8209http://dx.doi.org/10.3816/CBC.2004.n.011Google Scholar

2. 

J. S. Rosset al., “Targeted therapy in breast cancer: the HER-2/neu gene and protein,” Mol. Cell Proteomics 3(4), 379–398 (2004).MCPOBS1535-9476http://dx.doi.org/10.1074/mcp.R400001-MCP200Google Scholar

3. 

D. J. Slamonet al., “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science 235(4785), 177–182 (1987).SCIEAS0036-8075http://dx.doi.org/10.1126/science.3798106Google Scholar

4. 

D.J. Slamonet al., “Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer,” Science 244(4905), 707–712 (1989).SCIEAS0036-8075http://dx.doi.org/10.1126/science.2470152Google Scholar

5. 

G. Konecnyet al., “Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer,” J. Natl. Cancer Inst. 95(2), 142–153 (2003).JNCIEQhttp://dx.doi.org/10.1093/jnci/95.2.142Google Scholar

6. 

R. NahtaF. J. Esteva, “HER2 therapy: molecular mechanisms of trastuzumab resistance,” Breast Cancer Res. 8(6), 215–222 (2006).BCTRD6http://dx.doi.org/10.1186/bcr1612Google Scholar

7. 

E. Grimmet al., “Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases,” Am. J. Clin. Pathol. 134(2), 284–292 (2010).AJCPAI0002-9173http://dx.doi.org/10.1309/AJCPUQB18XZOHHBJGoogle Scholar

8. 

M. Hoanget al., “HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma,” Am. J. Clin. Pathol. 113(6), 852–859 (2000).AJCPAI0002-9173http://dx.doi.org/10.1309/VACP-VLQA-G9DX-VUDFGoogle Scholar

9. 

H. Tsudaet al., “Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression,” Cancer 92(12), 2965–2974 (2001).CANCAR1097-0142http://dx.doi.org/10.1002/(ISSN)1097-0142Google Scholar

10. 

L. Hammocket al., “Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization,” Hum. Pathol. 34(10), 1043–1047 (2003).HPCQA40046-8177http://dx.doi.org/10.1053/S0046-8177(03)00409-XGoogle Scholar

11. 

A. Sińczak-Kutaet al., “Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods,” Pol. J. Pathol. 58(1), 41–50 (2007).PJUPE51233-9687Google Scholar

12. 

D. Rusnaket al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Mol. Cancer Ther. 1(2), 85–94 (2001).MCTOCF1535-7163Google Scholar

13. 

W. Xiaet al., “Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways,” Oncogene 21(41), 6255–6263 (2002).ONCNES0950-9232http://dx.doi.org/10.1038/sj.onc.1205794Google Scholar

14. 

G. Konecnyet al., “Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells,” Cancer Res. 66(3), 1630–1639 (2006).CNREA80008-5472http://dx.doi.org/10.1158/0008-5472.CAN-05-1182Google Scholar

15. 

A. S. Hakaet al., “Diagnosing breast cancer by using Raman spectroscopy,” Proc. Natl. Acad. Sci. U. S. A. 102(35), 12371–12376 (2005).PNASA60027-8424http://dx.doi.org/10.1073/pnas.0501390102Google Scholar

16. 

S. K. Majumderet al., “Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination,” J. Biomed. Opt. 13(5), 054009 (2008).JBOPFO1083-3668http://dx.doi.org/10.1117/1.2975962Google Scholar

17. 

R. E. Kastet al., “Raman spectroscopy can differentiate malignant tumors from normal breast tissue and detect early neoplastic changes in a mouse model,” Biopolymers 89(3), 235–241 (2008).BIPMAA0006-3525http://dx.doi.org/10.1002/(ISSN)1097-0282Google Scholar

18. 

C. Yuet al., “Characterization of human breast epithelial cells by confocal Raman microspectroscopy,” Cancer Detect. Prev. 30(6), 515–522 (2006).CDPRD40361-090Xhttp://dx.doi.org/10.1016/j.cdp.2006.10.007Google Scholar

19. 

M. V. Chowdaryet al., “Discrimination of normal, benign, and malignant breast tissues by Raman spectroscopy,” Biopolymers 83(5), 556–569 (2006).BIPMAA0006-3525http://dx.doi.org/10.1002/(ISSN)1097-0282Google Scholar

20. 

S. Leeet al., “Surface-enhanced Raman scattering imaging of HER2 cancer markers overexpressed in single MCF7 cells using antibody conjugated hollow gold nanospheres,” Biosens. Bioelectron. 24(7), 2260–2263 (2009).BBIOE40956-5663http://dx.doi.org/10.1016/j.bios.2008.10.018Google Scholar

21. 

J. Yanget al., “Distinguishing breast cancer cells using surface-enhanced Raman scattering,” Anal. Bioanal. Chem. 402(3),1093–1100 (2012).ABCNBP1618-2642http://dx.doi.org/10.1007/s00216-011-5577-zGoogle Scholar

22. 

G. J. Puppelset al., “Studying single living cells and chromosomes by confocal Raman microspectroscopy,” Nature 347(6290), 301–303 (1990).NATUAS0028-0836http://dx.doi.org/10.1038/347301a0Google Scholar

23. 

L. Hartsuikeret al., “A comparison of breast cancer tumor cells with varying expression of the Her2/neu receptor by Raman microspectroscopic imaging,” Analyst 135(12), 3220–3226 (2010).ANLYAG0365-4885http://dx.doi.org/10.1039/c0an00524jGoogle Scholar

24. 

Y. Uedaet al., “Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility,” J. Biol. Chem. 279(23), 24505–24513 (2004).JBCHA30021-9258http://dx.doi.org/10.1074/jbc.M400081200Google Scholar

25. 

J. EngelmanL. Cantley, “The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors,” Clin. Cancer Res. 12(14 Pt 2), 4372s–4376s (2006).CCREF41078-0432http://dx.doi.org/10.1158/1078-0432.CCR-06-0795Google Scholar

26. 

C. A. Ritteret al., “Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network,” Clin. Cancer Res. 13(16), 4909–4919 (2007).CCREF41078-0432http://dx.doi.org/10.1158/1078-0432.CCR-07-0701Google Scholar

27. 

B. Rexeret al., “Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition,” Oncogene 30, 4163–4237 (2011).ONCNES0950-9232http://dx.doi.org/10.1038/onc.2011.130Google Scholar

28. 

C. A. LieberA. Mahadevan-Jansen, “Automated method for subtraction of fluorescence from biological Raman spectra,” Appl. Spectrosc. 57(11), 1363–1367 (2003).APSPA40003-7028http://dx.doi.org/10.1366/000370203322554518Google Scholar

29. 

I. J. PenceE. VargisA. Mahadevan-Jansen, “Assessing variability of in vivo tissue Raman spectra,” Appl. Spectrosc. 67(7), 789–800 (2013).APSPA40003-7028http://dx.doi.org/10.1366/12-06773Google Scholar

30. 

J. FriedmanT. HastieR. Tibshirani, “Sparse inverse covariance estimation with the graphical lasso,” Biostatistics 9(3), 432–441 (2008).1465-4644http://dx.doi.org/10.1093/biostatistics/kxm045Google Scholar

31. 

J. H. FriedmanR. Tibshirani, “Regularization paths for generalized linear models via coordinate descent,” J. Stat. Softw. 33(1), 1–22 (2010).1548-7660Google Scholar

32. 

C. Krafftet al., “Near infrared Raman spectra of human brain lipids,” Spectrochim. Acta A Mol. Biomol. Spectrosc. 61, 1529–1564 (2005).SAMCAS1386-1425http://dx.doi.org/10.1016/j.saa.2004.11.017Google Scholar

33. 

K. Dehringet al., “Correlating changes in collagen secondary structure with aging and defective type II collagen by Raman spectroscopy,” Appl. Spectrosc. 60, 366–438 (2006).APSPA40003-7028http://dx.doi.org/10.1366/000370206776593582Google Scholar

34. 

Y. GuanG. Thomas, “Vibrational analysis of nucleic acids. IV. Normal modes of the DNA phosphodiester structure modeled by diethyl phosphate,” Biopolymers 39, 813–848 (1996).BIPMAA0006-3525http://dx.doi.org/10.1002/(SICI)1097-0282(199612)39:6<813::AID-BIP7>3.3.CO;2-CGoogle Scholar

35. 

Z. Huanget al., “Near-infrared Raman spectroscopy for optical diagnosis of lung cancer,” Int. J. Cancer 107(6), 1047–1052 (2003).IJCNAW1097-0215http://dx.doi.org/10.1002/(ISSN)1097-0215Google Scholar

36. 

W.-T. Chenget al., “Micro-Raman spectroscopy used to identify and grade human skin pilomatrixoma,” Microsc. Res. Tech. 68, 75–84 (2005).MRTEEO1059-910Xhttp://dx.doi.org/10.1002/(ISSN)1097-0029Google Scholar

37. 

R. ManoharanY. WangM. Feld, “Histochemical analysis of biological tissues using Raman spectroscopy,” Spectrochim. Acta A 52, 35 (1996).1386-1425http://dx.doi.org/10.1016/0584-8539(95)01573-6Google Scholar

38. 

M. L. ParetS. K. SharmaA. M. Alvarez, “Characterization of biofumigated Ralstonia solanacearum cells using micro-Raman spectroscopy and electron microscopy,” Phytopathology 102(1), 105–113 (2012).PHYTAJ0031-949Xhttp://dx.doi.org/10.1094/PHYTO-12-10-0330Google Scholar

39. 

C. FrankR. McCreeryD. Redd, “Raman spectroscopy of normal and diseased human breast tissues,” Anal. Chem. 67(5), 777–783 (1995).ANCHAM0003-2700http://dx.doi.org/10.1021/ac00101a001Google Scholar

40. 

Z. MovasaghiS. RehmanI. U. Rehman, “Raman spectroscopy of biological tissues,” Appl. Spectrosc. 42(5), 493–541 (2007).APSPA40003-7028http://dx.doi.org/10.1080/05704920701551530Google Scholar

41. 

Q. Wuet al., “Intensities of E. coli nucleic acid Raman spectra excited selectively from whole cells with 251-nm light,” Anal. Chem. 72(13), 2981–2986 (2000).ANCHAM0003-2700http://dx.doi.org/10.1021/ac990932pGoogle Scholar

42. 

K. A. HartmanN. ClaytonG. J. Thomas Jr., “Studies of viral structure by Raman spectroscopy. I. R17 virus and R17 RNA,” Biochem. Biophys. Res. Commun. 50(3), 942–949 (1973).BBRCA90006-291Xhttp://dx.doi.org/10.1016/0006-291X(73)91336-3Google Scholar

43. 

J. MenendezR. Lupu, “Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis,” Nat. Rev. Cancer 7(10), 763–777 (2007).NRCAC41474-175Xhttp://dx.doi.org/10.1038/nrc2222Google Scholar

44. 

A. Vazquez-Martinet al., “Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells,” Cell Proliferation 41(1), 59–85 (2008).CPROEM1365-2184http://dx.doi.org/10.1111/j.1365-2184.2007.00498.xGoogle Scholar

45. 

J. Menendezet al., “Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells,” PNAS 101(29), 10715–10720 (2004).PNASA60027-8424http://dx.doi.org/10.1073/pnas.0403390101Google Scholar

46. 

J. MenendezL. VellonR. Lupu, “Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells,” Med. Hypotheses 64, 997–1998 (2005).MEHYDY0306-9877http://dx.doi.org/10.1016/j.mehy.2004.09.027Google Scholar

47. 

N. Spectoret al., “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies,” J. Clin. Oncol. 23(11), 2502–2512 (2005).JCONDN0732-183Xhttp://dx.doi.org/10.1200/JCO.2005.12.157Google Scholar

48. 

R. LupuJ. Menendez, “Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?” Endocrinology 147(9), 4056–4066 (2006).ENDOAO0013-7227Google Scholar

49. 

T. Puiget al., “A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines,” Breast Cancer Res. 13(6), R131–R143 (2011).BCTRD6http://dx.doi.org/10.1186/bcr3077Google Scholar

Biography

Xiaohong Bi is an assistant professor of nanomedicine and biomedical engineering at the University of Texas Health Science Center at Houston. She received her BS degree in biochemistry from Nanjing University, China, and her MS and PhD degrees in chemistry from Rutgers University, Newark. Her research focuses on the development of optical techniques for pathogenesis characterization and cancer theragnosis.

Brent Rexer is an assistant professor of medicine at Vanderbilt University. He completed fellowship and residency training in hematology/oncology at Vanderbilt University Medical Center, after attending medical school at Vanderbilt and earning a PhD degree in biochemistry. His research aims to understand mechanisms of resistance to targeted therapies in cancer and to identify potential therapies to overcome that resistance. In particular, he is focused on studying resistance to lapatinib in breast cancer.

Carlos L. Arteaga obtained his MD at the University of Guayaquil in Ecuador. He trained in internal medicine and medical oncology at Emory University and the University of Texas Health Sciences Center in San Antonio, respectively. He holds the Donna S. Hall Chair in Breast Cancer Research and serves as a professor of medicine and cancer biology, an associate director for translational/clinical research, and a director of the Breast Cancer Program of the Vanderbilt-Ingram Cancer Center at Vanderbilt University.

Mingsheng Guo is a bioinformatician at the Center for Quantitative Sciences at Vanderbilt University. He received his PhD degree from Nanjing University in China. Previously, he worked on the application of Raman spectroscopy for cornea laser surgery and characterization of antifreeze glycoprotein at Fisk University. His current research focuses on the feature discrimination of Raman spectra and the analysis of RNA/DNA sequence.

Anita Mahadevan-Jansen received her BS and MS degrees in physics from the University of Bombay, India, and an MS and PhD degrees in biomedical engineering from the University of Texas at Austin. She joined the Vanderbilt Engineering Faculty in 1996. She is currently the Orrin H. Ingram Professor of Biomedical Engineering at Vanderbilt University and holds a secondary appointment in the Department of Neurological Surgery.

Xiaohong Bi, Brent Rexer, Carlos L. Arteaga, Mingsheng Guo, Anita Mahadevan-Jansen, "Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy," Journal of Biomedical Optics 19(2), 025001 (4 February 2014). http://dx.doi.org/10.1117/1.JBO.19.2.025001
Submission: Received ; Accepted
JOURNAL ARTICLE
7 PAGES


SHARE
KEYWORDS
Breast cancer

Raman spectroscopy

Resistance

Cancer

Remote sensing

Statistical analysis

Proteins

Back to Top